TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04078464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Training Alone
Description: Participants will lie down and listen to a pre-recorded guided mindfulness meditation for 36 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Physical Activity Alone
Description: Physical activity will include a 6 minute stretching session, 1 minute transition to treadmill, 3 minute warm up at a participant chosen pace on the treadmill, 20 minutes of walking at a moderate pace at target heart rate, 3 minute cool down at 2.0-2.5 mph, 1 minute transition off treadmill and 2 minutes of stretching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Physical Activity and Mindfulness Training Together
Description: Participants will listen to a pre-recorded mindfulness meditation which will guide them through a 6 minute stretching session, 1 minute transition to treadmill, 3 minute warm up at a participant chosen pace on the treadmill, 20 minutes of walking at a moderate pace at target heart rate, 3 minute cool down at 2.0-2.5 mph, 1 minute transition off treadmill and 2 minutes of stretching.
Study: NCT04477135

Intervention type: OTHER
Group type: OTHER
Intervention: upper extremity pain
Description: upper extremity pain in perinatologists due to working actively and performing ultrasonography every day

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrasonography
Description: ultrasonography
Study: NCT04165122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HDIT101
Description: i.v. Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valaciclovir
Description: oral application of encapsulated Valaciclovir tablets

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HDIT101 placebo
Description: i.v. Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir placebo
Description: oral application of encapsulated Valaciclovir placebo tablets
Study: NCT01166919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Matrix Radiofrequency
Description: Matrix Radiofrequency Treatment of Port Wine Stain Birthmarks
Study: NCT01987856

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blastocyst morphology
Description: microscopic examination only

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blastocyst morphology
Description: microscopic examination only
Study: NCT03174444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small Media
Description: Bilingual brochures and access to bilingual website
Study: NCT02121977

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elevate Anterior and Apical

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Native Tissue Repair for pelvic organ prolapse
Study: NCT03473405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air Barrier System
Description: The Air Barrier System is a device that uses localized clean air flow to shield a surgery site from ambient airborne microorganisms that are shed into the air from people present in the operating room.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The Air Barrier System will be deployed onto the surgical field, but the airflow will not be activated, so this is a sham control comparator.
Study: NCT01868659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diagnostic checklist
Description: Diagnostic checklist used before patient discharged

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care with no diagnostic checklist
Description: Patient receives usual care with no research intervention
Study: NCT00467350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG 3350
Description: PEG 3350 1.5 gram/kg for disimpaction then 0.8 gram/kg for maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: milk and molasses enema
Description: enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance
Study: NCT02527863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Description: 60 mg Tolvaptan pr day for 1 day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet Unikalk pr day for 1 day
Study: NCT03627013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol-N Solution
Description: Perfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol-N Solution
Description: Perfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol-N Solution
Description: Perfusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Custodiol HTK Solution
Description: Perfusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Custodiol HTK Solution
Description: Perfusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Custodiol HTK Solution
Description: Perfusion
Study: NCT03991208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malarone
Description: Malarone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Malarone
Description: Malarone
Study: NCT03230877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toffee full face mask with 'Improved Seal'
Description: Participants will be randomized to this arm for a total of 7 ± 4 days from visit 1. Participants will be using the Improved Seal in this treatment arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toffee full face mask with 'Improved Seal'
Description: Participants will be randomized to this arm for a total of 7 ± 4 days from visit 1. Participants will be using the Improved Seal in this treatment arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toffee full face mask with 'Normal Seal'
Description: Participants will be randomized to this arm for a total of 7 ± 4 days from visit 1. Participants will be using the Normal Seal in this treatment arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toffee full face mask with 'Normal Seal'
Description: Participants will be randomized to this arm for a total of 7 ± 4 days from visit 1. Participants will be using the Normal Seal in this treatment arm.
Study: NCT04571450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reintervention
Description: This self-applied online program will take three months and comprise 9 behavioural modules developed gradually, achieving the changes needed on eating and physical activity habits, supported by audiovisual instructions given by an hypertension specialist doctor.
Study: NCT02046629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide HMR1726
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholestyramine
Description: Pharmaceutical form:power Route of administration: oral
Study: NCT04824690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Immersive virtual reality tour of the operating theatre before surgery and distraction methods both using VR headset
Study: NCT04879953

Intervention type: DRUG
Intervention: PIPAC with systemic chemotherapy
Description: PIPAC procedures were performed every 6 to 8 weeks, alternating with systemic chemotherapy, replacing a cycle of intravenous chemotherapy.

Intervention type: DRUG
Intervention: Systemic chemotherapy alone
Description: Intravenous chemotherapy
Study: NCT01685723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling group
Description: Subjects will receive brief advice based on risk communication by a nurse counselor. The brief advice will be based on a specifically-designed risk communication leaflet that warns about the risks of continued smoking for subjects' cancer treatment and prognosis. Subjects will receive a booster intervention via telephone at 1 week to assess the progress of and barriers to the subjects' action plans and identifying individual difficulties and facilitators towards quitting. They also receive a generic standard self-help smoking cessation booklet.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: General supporting
Description: Subjects in this group will receive a generic self-help smoking cessation booklet and standard care without risk communication. They will have the same follow-up sections as the intervention group to receive diseases support.
Study: NCT01929629

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A
Description: Single ascending doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B
Description: Single doses food effect. Subjects to receive 2 single doses, one in fed and one in fasted.
Study: NCT00072449

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study: NCT03515746

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exergaming in virtual environment
Description: The 10 cubes task will be performed in virtual environment - either in 2D on a laptop computer or in 3D using 3D goggles

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exergaming in virtual environment
Description: The 10 cubes task will be performed in virtual environment - either in 2D on a laptop computer or in 3D using 3D goggles
Study: NCT02801032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Single dose, 20 mg capsule p.o. minimum one week apart from placebo.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, matching capsule p.o. minimum one week apart from active treatment.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention.
Study: NCT02367547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hexylaminolevulinate cream
Description: The cream is mixed up by the Pharmacy Yliopiston Apteekki for the study and every set is analysed by mass spectrometry.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid Nano Emulsion
Description: In the study we use Ameluz.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylaminolevulinate cream
Description: In the study we use Metvix.
Study: NCT03635372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alginate
Description: 10 cc of Alginate peroral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucralfate
Description: 10 cc of Sucralfate peroral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrotalcite
Description: 10 cc of Hydrotalcite peroral
Study: NCT04014595

Intervention type: PROCEDURE
Intervention: Rotational atherectomy in combination with cutting balloon
Description: Treatment of severely calcified coronary lesion using rotational atherectomy followed by balloon angioplasty using a cutting balloon and Implantation of the hybrid sirolimus-eluting stent.
Study: NCT03130153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Powder
Description: Aspirin powder to be dissolved in water and to be used as mouthwash twice daily for 7 days after tooth extraction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Powder
Description: Aspirin powder to be dissolved in water and to be used as mouthwash twice daily for 7 days after tooth extraction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline to be used as mouthwash twice daily for 7 days after tooth extraction among non-hypertensive subjects.
Study: NCT03031145

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Felis Domesticus
Description: Nasal Administration of Felis Domesticus

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Felis Domesticus
Description: Nasal Administration of Felis Domesticus

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Felis Domesticus
Description: Nasal Administration of Felis Domesticus
Study: NCT01318395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: orally 150 mg/d for 1 week, then orally 300 mg/d for 7 weeks
Study: NCT03228901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Administration of the hormone oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT04500951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized resting environment
Description: Alarms from feeding pumps will be relayed to the nurse call system for all intervention periods. Alternatively meals will be timewise reorganized to not interfer with the intervention resting periods. Signs reminding staff not to disturb will be posted for all intervention periods.~For each patient the close team of rehabilitation professionals will agree upon a guideline suggesting the optimal resting environment for the specific patient. The guideline wil be based on knowledge gathered from relatives on pre-injury preferences. Furthermore, the guideline will be developed based on a toolbox of possible intervention representing best practice. The toolbox has been designed according to the categories of the International Classification of Functioning.~The intervention will designed individually for each patient.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard resting environment
Description: The control condition, standard resting environment, will consist of a basic positioning either reclined in bed or reclined in wheelchair according to regular procedures of the ward. Pressure ulcers and positioning believed to induce pain will be avoided.
Study: NCT01318395

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally once per day
Study: NCT03288038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Study: NCT02398110

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal NOTES nephrectomy
Description: A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transvaginal NOTES nephrectomy
Description: A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopic nephrectomy
Description: One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional laparoscopic nephrectomy
Description: One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin
Study: NCT01464268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Administration of riboflavin every 2 minutes for the duration of UV exposure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: Administration of riboflavin every 1 minute for the duration of UV exposure.
Study: NCT00983372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered alone at 7:15 am on Day 1 after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem ER
Description: One 240 mg diltiazem ER capsule administered daily at 7:15 am on Days 15 to 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered along with diltiazem ER at 7:15 am on Day 21 after an overnight fast of at least 10 hours.
Study: NCT02133157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfatinib
Description: Sulfatinib is a capsule in the form of25, 50mg , 100mg; oral, once a day
Study: NCT04151264

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hypotension probability index (HPI)
Description: The intervention group is managed with the HPI parameter to detect and possibly prevent hypotension during anaesthesia.
Study: NCT02016989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RGTA OTR4120 (CACICOL20)

Intervention type: DEVICE
Group type: OTHER
Intervention: physiological salt solution
Study: NCT04737733

Intervention type: OTHER
Group type: OTHER
Intervention: The dementia friendly program
Description: Implementation of a systematic screening and risk modification and management plan, to identify and enhance the management of patients with cognitive impairment and risk of delirium.
Study: NCT04071379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis B + DTP-HB-Hib
Description: 1 dose of 0.5 ml Recombinant Hepatitis B + 3 dose of 0.5 ml of DTP-HB-Hib

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hep B + Pentabio (registered)
Description: 1 dose of 0.5 ml Recombinant Hepatitis B (registered) + 3 dose of 0.5 ml of Pentabio (registered)
Study: NCT02677428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remotely-Delivered Benefits Counseling
Description: Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
Study: NCT04077892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: SAR patients received treatment of a combination of budesonide and montelukast tablet or only intranasal budesonide randomly for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide
Description: SAR patients received treatment of a combination of budesonide and montelukast tablet or only intranasal budesonide randomly for 14 days
Study: NCT00998569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurocognitive Enhancement
Description: Neurocognitive Enhancement Therapy (NET) uses behavioural treatment strategies that are designed to improve a range of cognitive skills. NET uses strategies such as coaching, repetition, practice, teaching, group discussion, and compensation for deficits by using cognitive strengths.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait List
Description: Participants will be wait listed for 10 weeks, following which time they will receive the intervention previously described.
Study: NCT03864081

Intervention type: DEVICE
Group type: OTHER
Intervention: Phase Signal Recorder
Description: The Phase Signal Acquisition (PSAQ) System is a medical device system that is being developed to collect phase signals from patients to support the development and testing of machine learned algorithms. The PSAQ System consists of two components that work together to acquire and transmit the phase signals and patient specific data to a secured, cloud-based repository. The PSAQ System is comprised of: 1) the Phase Signal Recorder (PSR) which is a portable instrument, and 2) the Phase Signal Data Repository (PSDR) which is a cloud based data repository. Data collected during this study will not be used to guide treatment.
Study: NCT02793986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: For patients in Group P, the sedation was achieved with a target-controlled infusion (TCI) of propofol, and the effect site concentration was set to 0.8-1.0μg/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: For patients in Group D, the sedation was achieved with a bolus of dexmedetomidine at 1.0 μg/kg (over a period of 15 to 20 min) and followed by an infusion of dexmedetomidine at 0.2-0.7 μg/kg/h. The depth of sedation was considered enough when patient was unresponsive to voice.
Study: NCT05253014

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sphenopalatine ganglion block
Description: block of the sphenopalatine ganglion using either lidocaine or bupivacaine to relief postdural puncture headache

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sphenopalatine ganglion block
Description: block of the sphenopalatine ganglion using either lidocaine or bupivacaine to relief postdural puncture headache

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: intravenous paracetamol every 8 hours